熱門資訊> 正文
BridgeBio Oncology获得雷蒙德·詹姆斯（Raymond James）的跑赢大盘评级
2026-01-10 04:59
- Raymond James initiated BridgeBio Oncology Therapeutics (BBOT) at outperform, noting the company is well capitalized and has several phase 1 data readouts this year.
- The firm set a $24 price target (~80% upside based on Jan. 8 close).
- BridgeBio has three candidates in phase 1: BBO-8520 for KRASG12C mutant non-small cell lung cancer; BBO-11818 for KRAS mutant solid tumors; and BBO-10203 for HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer.
- Analyst Sean McCutcheon said that the readouts "will continue to strengthen the company’s positioning as an emerging player," adding that the company is "well positioned in an increasingly competitive environment."
More on BridgeBio Oncology Therapeutics
- BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least
- BridgeBio Oncology Therapeutics, Inc. GAAP EPS of -$1.03
- Seeking Alpha’s Quant Rating on BridgeBio Oncology Therapeutics, Inc.
- Historical earnings data for BridgeBio Oncology Therapeutics, Inc.
- Financial information for BridgeBio Oncology Therapeutics, Inc.
推薦文章
華盛早報 | 特朗普再發驚人言論！美元跌至四年低谷，金價續創新高；聯合健康績后重挫近20%
1月28日外盤頭條：美元跌至四年低點 特朗普稱不擔心 谷歌推出低價版AI Plus 特朗普關税落地概率不足三成
美股機會日報 | 美光擬豪擲240億美元擴產存儲芯片！聯合健康遭雙重利空打擊，盤前暴跌15%
再出手飆漲超60%！特朗普政府重金入股美稀土公司，這份「關鍵礦產公司名單」請收好
華盛早報 | 特朗普突發貿易威脅！對韓國加税至25%；白銀「深V」閃崩后又急升
新股申購 | 國恩科技今起招股！一手入場費8484.71港元
特朗普政府16億美元入股美國稀土公司，佈局稀土供應鏈
摩根士丹利和美銀看好新興市場套利交易 去年回報已創2009年以來最強
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
